Cancers driven by faulty RAS genes have long been seen as a locked door: until recently, designing a drug that could successfully target these mutations was not thought possible. Now early results from a clinical trial of an experimental drug called ERAS-0015 suggest that door may be starting to open. The patients had hard-to-treat pancreatic and lung cancers and had already tried other treatments. In a notable share of them, the drug shrank tumours while causing relatively few severe side effects. The findings come from AURORAS-1, the first trial of the drug in humans. They were reported in Barcelona, Spain, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which ran from 18 to 20 November 2026.
A switch stuck in the 'on' position
RAS genes make proteins that act like switches, passing along signals that tell cells to grow. Certain mutations jam that switch in the "on" position. It then keeps sending growth signals that can start a cancer and keep it going. ERAS-0015 is described as a pan-RAS molecular glue. In plain terms, it is a molecule that holds proteins together in a way that shuts down these runaway signals. It is designed to latch onto the RAS switch while it is switched on. Because it is "pan-RAS", it aims to block signals from several different cancer-causing RAS mutations rather than just one.
Dr. Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute in Sarasota, US, presented the results. She framed the work as part of precision oncology: matching the specific weak spot in a person's cancer, which she called its "Achilles heel", to a drug that hits it directly.
What the trial found
AURORAS-1 began in June 2025. It is testing ERAS-0015 both alone and alongside other cancer therapies in people with various RAS-mutant solid tumours. These include non-small cell lung cancer (NSCLC) that has spread beyond its original site, pancreatic cancer and colorectal cancer. The findings came from 148 patients, with results reported for 83 people with pancreatic cancer and 37 with NSCLC. Enrolment is still ongoing.
Doses ranged from 2 mg up to 40 mg. Over a median follow-up of just over four months, researchers saw no sign of reaching the maximum tolerated dose, the highest amount that can be given before side effects become unacceptable. Key results at the 32 mg dose included:
- Among 25 pancreatic cancer patients who had already had chemotherapy, tumours shrank in 11 (44%).
- Among five lung cancer patients whose earlier treatment included an immune checkpoint inhibitor or platinum-based chemotherapy, tumours shrank in three (60%).
Wang explained that a "response" here means substantial tumour shrinkage. She said these rates show "clinically meaningful activity" in patient groups with few, if any, other options.
Side effects
At doses of 16 to 32 mg, at least one in ten patients experienced each of the most common side effects. These were rash, diarrhoea, nausea and inflammation of the mouth lining. Twelve patients (9.8%) had severe treatment-related side effects, classed as grade 3 or higher. None of the side effects forced doctors to limit the dose.
Small numbers, big caveats
Like all Phase I trials, which focus on safety and finding the right dose, this study involved only a limited number of patients. The lung cancer result at 32 mg, for example, rests on just five people. The researchers say confirming whether ERAS-0015 is safe and effective will require larger studies, including Phase II and III trials.
"If these early results are confirmed, ERAS-0015 could offer patients with RAS-driven cancers a new option," Wang said.
Elena Garralda chairs the symposium and co-directs clinical research at the Vall d'Hebron Institute of Oncology. She was not involved in the study. She noted that this was the first presentation of the AURORAS-1 results and called them "eagerly awaited". She also described the drug's antitumour activity as encouraging. According to Garralda, this was one of several studies at the meeting beginning to show that drugs targeting RAS-driven cancers can be designed after all, something "not thought possible until recently."
Sources: Medical Xpress. Image: Pixabay / CC0 Public Domain.
Comments
Please login to leave a comment Sign in